يعرض 1 - 7 نتائج من 7 نتيجة بحث عن '"Mario Liste-Hermoso"', وقت الاستعلام: 0.69s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer

    المؤلفون: Carlos H. Barrios, Shigehira Saji, Nadia Harbeck, Hong Zhang, Kyung H. Jung, Sheetal Patel, Shilpen Patel, Anh Nguyen Duc, Mario Liste-Hermoso, Stephen Y. Chui, Elizabeth A. Mittendorf

    المصدر: npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)

    مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

    وصف الملف: electronic resource

    العلاقة: https://doaj.org/toc/2374-4677Test

    الوصول الحر: https://doaj.org/article/7bdcd76cbfff4bc7bdbcff2271b8e1e3Test

    View record in DOAJ النص الكامل

    أضف إلى المفضلة
  2. 2
    Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

    المؤلفون: Luciana Molinero, Melinda L. Telli, Vidya Maiya, Hiroji Iwata, Kevin Punie, Mario Liste-Hermoso, Carlos H. Barrios, Andreas Koehler, Elizabeth A. Mittendorf, Frédérique Penault-Llorca, Shilpen Patel, Anh Nguyen Duc, Cristiano Ferrario, Joohyuk Sohn, Roberto Hegg, Shigehira Saji, Stephen Y. Chui, Kyung Hae Jung, Nadia Harbeck, Hong Zhang

    المساهمون: Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER

    المصدر: The Lancet
    The Lancet, Elsevier, 2020, 396 (10257), pp.1090-1100. ⟨10.1016/S0140-6736(20)31953-X⟩

    مصطلحات موضوعية: medicine.medical_treatment, [SDV]Life Sciences [q-bio], Triple Negative Breast Neoplasms, 030204 cardiovascular system & hematology, Gastroenterology, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, MESH: Double-Blind Method, 030212 general & internal medicine, Neoadjuvant therapy, Triple-negative breast cancer, education.field_of_study, MESH: Middle Aged, General Medicine, MESH: Triple Negative Breast Neoplasms, Middle Aged, Neoadjuvant Therapy, 3. Good health, MESH: Antineoplastic Combined Chemotherapy Protocols, Female, medicine.drug, Adult, medicine.medical_specialty, Cyclophosphamide, Anthracycline, Paclitaxel, Population, MESH: Neoadjuvant Therapy, Antineoplastic Agents, Placebo, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, MESH: Doxorubicin, Double-Blind Method, Atezolizumab, Internal medicine, Albumins, Humans, MESH: Paclitaxel, education, Chemotherapy, MESH: Humans, business.industry, MESH: Cyclophosphamide, MESH: Adult, Doxorubicin, MESH: Antibodies, Monoclonal, Humanized, MESH: Antineoplastic Agents, MESH: Albumins, business, MESH: Female

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::221e52d5af8d01ad9b7f0473fadec775Test
    https://hal.archives-ouvertes.fr/hal-03046446Test


    أضف إلى المفضلة
  3. 3
    Abstract LB162: Evaluation of tumor immune biomarkers with pathologic complete response (pCR) in patients receiving atezolizumab + chemotherapy in early triple negative breast cancer (eTNBC): exploratory analyses from the IMpassion031 study

    المؤلفون: Shigehira Saji, Mario Liste-Hermoso, Stephen Y. Chui, Hong Zhang, Elizabeth A. Mittendorf, Shilpen Patel, Kyung Hae Jung, Nadia Harbeck, Ching-Wei Chang, Luciana Molinero, Carlos H. Barrios

    المصدر: Cancer Research. 81:LB162-LB162

    مصطلحات موضوعية: Oncology, Cancer Research, Chemotherapy, medicine.medical_specialty, Cyclophosphamide, business.industry, medicine.medical_treatment, Cancer, medicine.disease, Placebo, Immune system, Atezolizumab, Internal medicine, medicine, Doxorubicin, business, Triple-negative breast cancer, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::9ed83361ca70479aa65a1eb4a098fdcdTest
    https://doi.org/10.1158/1538-7445.am2021-lb162Test


    أضف إلى المفضلة
  4. 4
    Abstract PD12-11: Patient-reported outcomes from the Phase III IMpassion031 trial of neoadjuvant atezolizumab + chemotherapy in early triple-negative breast cancer

    المؤلفون: Anh Nguyen Duc, Nadia Harbeck, Carlos Barrios, Mario Liste-Hermoso, Kyung Hae Jung, Hong Zhang, Shilpen Patel, Shigehira Saji, Stephen Y. Chui, Sheetal Patel, Elizabeth A. Mittendorf

    المصدر: Cancer Research. 81:PD12-11

    مصطلحات موضوعية: Oncology, Cancer Research, Chemotherapy, medicine.medical_specialty, business.industry, Atezolizumab, medicine.medical_treatment, Internal medicine, Medicine, business, Triple-negative breast cancer

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::de5063b0ac15539261d16e291e63baebTest
    https://doi.org/10.1158/1538-7445.sabcs20-pd12-11Test


    أضف إلى المفضلة
  5. 5
    Abstract GS3-02: Patient-reported outcomes (PROs) from the Ph 3 IMpassion031 trial of neoadjuvant (NA) atezolizumab + chemo in early triple-negative breast cancer (eTNBC)

    المؤلفون: Shilpen Patel, Anh Nguyen Duc, Kyung Hae Jung, E Mittendorf, Shigehira Saji, Carlos H. Barrios, Sheetal Patel, Hong Zhang, Stephen Y. Chui, Nadia Harbeck, Mario Liste-Hermoso

    المصدر: Cancer Research. 81:GS3-02

    مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Cyclophosphamide, business.industry, Nausea, medicine.disease, Placebo, Breast cancer, Oncology, Quality of life, Atezolizumab, Internal medicine, medicine, Clinical endpoint, Vomiting, medicine.symptom, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::5d1111ba274a7618f375991b2127aae9Test
    https://doi.org/10.1158/1538-7445.sabcs20-gs3-02Test


    أضف إلى المفضلة
  6. 6
    LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)

    المؤلفون: Cristiano Ferrario, Shigehira Saji, Luciana Molinero, Kevin Punie, A. Nguyen Duc, Melinda L. Telli, Hong Zhang, S.Y. Chui, Carlos H. Barrios, Mario Liste-Hermoso, Kyung Hwa Jung, Nadia Harbeck, H. Iwata, Joohyuk Sohn, A. Koehler, Vidya Maiya, Elizabeth A. Mittendorf, Roberto Hegg, Sheetal Patel, Frédérique Penault-Llorca

    المصدر: Annals of Oncology. 31:S1144

    مصطلحات موضوعية: Oncology, Chemotherapy, medicine.medical_specialty, Atezolizumab, business.industry, medicine.medical_treatment, Internal medicine, medicine, Hematology, business, Triple-negative breast cancer

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::6980f7859242c7a042d098e719da7356Test
    https://doi.org/10.1016/j.annonc.2020.08.2239Test


    أضف إلى المفضلة
  7. 7
    دورية أكاديمية
    Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

    المساهمون: Elizabeth A Mittendorf, Hong Zhang, Carlos H Barrios, Shigehira Saji, Kyung Hae Jung, Roberto Hegg, Andreas Koehler, Joohyuk Sohn, Hiroji Iwata, Melinda L Telli, Cristiano Ferrario, Kevin Punie, Frédérique Penault-Llorca, Shilpen Patel, Anh Nguyen Duc, Mario Liste-Hermoso, Vidya Maiya, Luciana Molinero, Stephen Y Chui, Nadia Harbeck, Sohn, Joo Hyuk

    مصطلحات موضوعية: Adult, Albumins / administration & dosage, Antibodies, Monoclonal, Humanized / administration & dosage, Humanized / adverse effects, Antineoplastic Agents / administration & dosage, Antineoplastic Agents / adverse effects, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Cyclophosphamide / administration & dosage, Cyclophosphamide / adverse effects, Double-Blind Method, Doxorubicin / administration & dosage, Doxorubicin / adverse effects, Female, Humans, Middle Aged, Neoadjuvant Therapy, Paclitaxel / administration & dosage, Triple Negative Breast Neoplasms / drug therapy

    العلاقة: LANCET; J02152; OAK-2021-05602; https://ir.ymlib.yonsei.ac.kr/handle/22282913/184907Test; https://www.sciencedirect.com/science/article/pii/S014067362031953XTest; T999202086; LANCET, Vol.396(10257) : 1090-1100, 2020-10

    الإتاحة: https://doi.org/10.1016/S0140-6736Test(20)31953-X
    https://ir.ymlib.yonsei.ac.kr/handle/22282913/184907Test
    https://www.sciencedirect.com/science/article/pii/S014067362031953XTest

    View record in BASE

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث